<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04832672</url>
  </required_header>
  <id_info>
    <org_study_id>NCC-005269</org_study_id>
    <nct_id>NCT04832672</nct_id>
  </id_info>
  <brief_title>Sequence of Radiation and Targeted Therapy in Brain Metastases</brief_title>
  <official_title>The Optimal Sequence of Intracranial Radiotherapy Compared to Systematic Tyrosine Kinase Inhibitors for Gene-driven Brain Metastases in Targeted Treatment Era</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conducted a single institutional, retrospective cohort study to demonstrate&#xD;
      the appropriate treatment strategy of upfront intracranial radiotherapy or upfront targeted&#xD;
      therapy in patients with brain metastases, including an assessment of its feasibility and&#xD;
      toxicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2010</start_date>
  <completion_date type="Actual">March 1, 2021</completion_date>
  <primary_completion_date type="Actual">March 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intracranial progression-free survival</measure>
    <time_frame>The interval from the start of initial intracranial treatment to first documented intracranial progression, or date of death from any cause, whichever came first, assessed up to 3 to 5 years</time_frame>
    <description>The survival time of patients before any intracranial progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>The time from the date of initial intracranial treatment until death from any cause or censored on the last follow-up, whichever came first, assessed up to 3 to 5 years</time_frame>
    <description>The survival time of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain metastasis-specific survival</measure>
    <time_frame>The interval from the start of initial intracranial treatment to death from brain metastases or censored on the last follow-up, whichever came first, assessed up to 3 to 5 years</time_frame>
    <description>The survival time of patients dead from brain metastases</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">570</enrollment>
  <condition>The Optimal Sequence of Radiotherapy and Systematic Tyrosine Kinase Inhibitors in Treating Brain Metastases</condition>
  <arm_group>
    <arm_group_label>The upfront radiotherapy group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>The upfront targeted-therapy group</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who underwent hypofractionated stereotactic radiotherapy planning at our&#xD;
        institution from October 2010 to October 2020&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Had histologically proven primary cancer.&#xD;
&#xD;
          -  Had newly diagnosed brain metastases in contrast-enhanced MRI.&#xD;
&#xD;
          -  Brain metastases focus should be measurable.&#xD;
&#xD;
          -  All the patients should safely receive radiotherapy and/or systematic tyrosine kinase&#xD;
             inhibitors.&#xD;
&#xD;
          -  Karnofsky performance score (KPS) ≥60 or KPS ≥40, but only caused by brain metastases.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with prior intracranial local treatments, such as surgery and radiotherapy&#xD;
             without dose prescription in detail&#xD;
&#xD;
          -  Patients with leptomeningeal metastases at first diagnosis.&#xD;
&#xD;
          -  Had synchronous or metachronous malignancies that might affect survival.&#xD;
&#xD;
          -  Had severe systemic diseases, abnormal conditions that might lead to incoordinate&#xD;
             behavior during the implementation of clinical measures.&#xD;
&#xD;
          -  Had incomplete sociodemographic and/or clinicopathologic baseline data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 2, 2021</study_first_submitted>
  <study_first_submitted_qc>April 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jianping Xiao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Brain metastases</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Targeted therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

